Liverpool COVID-19 Drug Interactions

The COVID-19 pandemic has affected every country in the world. It is well documented that those most susceptible to the worst outcomes of COVID-19 are the immunocompromised and those with underlying comorbidities. Therefore, patients requiring treatment for COVID-19 will also be on additional medication, posing a risk for drug-drug interactions (DDIs). In order to address this, the Liverpool Drug Interactions website team developed this freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of COVID-19 and commonly prescribed co-medications.

新冠疫情席卷全球，已有充分证据表明，易受新冠病毒最严重后果影响的群体为免疫系统受损者以及伴有基础合并症的患者。因此，需要接受新冠病毒治疗的患者也将同时服用其他药物，这增加了药物相互作用（DDIs）的风险。为此，利物浦药物相互作用网站团队开发了这一免费药物相互作用资源，旨在提供有关用于治疗新冠病毒的实验性药物与常用合用药之间相互作用可能性的信息。

搜集汇总

背景与挑战

背景概述

Liverpool COVID-19 Drug Interactions是一个专注于COVID-19治疗药物与常用合并用药之间相互作用的数据集，旨在帮助医疗专业人员评估药物相互作用风险，以改善患者治疗安全。该数据集由多个国际研究机构（如英国HIV协会、利物浦大学等）支持，涵盖生命科学、医学和药理学领域，数据开放访问且持续更新，最后更新于2024年5月22日。